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Abstract: Leukemic infiltration of the kidney is usually silent, and the admission of the patients 
with renal dysfunction or acute kidney injury is uncommon. We present a 34-year old hemodialysis 
patient with new onset of uncontrolled hypertension, erythropoietin-resistant anemia, thrombo-
cytopenia, and Bell’s palsy. On admission, his blood pressure (BP) was 210/110 mmHg and he 
had petechiae and purpura at upper and lower extremities. Renal ultrasonography (USG) showed 
bilaterally enlarged kidneys without hydronephrosis, unlike his previous USG, which determined 
bilaterally atrophic kidneys. Acute lymphoblastic leukemia, hypertensive crisis due to bilateral 
leukemic cell infiltration of kidneys, tumor lysis syndrome, and leukemic involvement of the facial 
nerve were diagnosed. Despite intense antihypertensive management, his BP was not controlled. 
After prednisolone, daunorubicine, and vincristine therapy, the size of kidneys diminished and his 
BP dropped under normal range. In conclusion, pathological findings such as uncontrolled hyper-
tension, flank pain, skin rashes, and abnormal blood count should be considered carefully, even in 
patients with end-stage renal disease receiving renal replacement therapy.
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Introduction
Acute lymphoblastic leukemia (ALL), while frequently diagnosed in children, can also 
be seen in adulthood. Patients with T-cell ALL and the M4 and M5 subtypes of acute 
myeloblastic leukemia are at a higher risk for extramedullary disease, including renal 
parenchymal involvement, which is the most frequent extramedullary   metastatic site.1 
Consequences of leukemic infiltration of the kidneys are asymptomatic bilateral renal 
enlargement, acute renal failure, and/or secondary hypertension, as reported previously. 
We report a patient with end-stage renal disease (ESRD), receiving hemodialysis, and 
uncontrolled hypertension due to leukemic cell infiltration of the kidneys.
Case
A 34-year-old man who had ESRD was admitted to the emergency room with com-
plaints of productive coughing, shortness of breath, and hypertension not controlled by 
his previous antihypertensive medication. He had been receiving hemodialysis three 
times weekly for 2 years. The etiology of his kidney disease could not be determined. 
He did not have diabetes or dyslipidemia. He had a history of generalized seizures and 
had used carbamazepine for 15 years. Despite iron supplementation and erythropoetin-
stimulating agent therapy, he had normochrome-normocytic anemia. His blood pressure 
(BP) was under control with ramipril 5 mg once daily and   amlodipin 5 mg once daily. 
Before admission, he also had had peripheral facial nerve palsy (Bell’s palsy) and was International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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treated with corticosteroid therapy for 3 weeks. On admission, 
he seemed pale, dyspneic, and agitated. His blood pressure 
was 210/110 mmHg. His heart rate was regular at 98 bpm, 
He was afebrile and had a 2/6 systolic ejection murmur on 
auscultation. He had crackles at the bases of the lungs and 
+/+ pedal edema bilaterally. There was not any audible bruit 
from the abdominal aorta and renal arteries. Bilateral upper 
and lower extremity arteries were palpable. He had petechiae 
and purpura at upper and lower extremities. His urine output 
was 500 mL/day.
The initial biochemistry and complete blood counts of 
the patient are shown in Table 1. Urinalysis revealed trace 
  protein, and no red blood cells per high-power field. There 
was no active urinary sediment. 24-hour urine protein was 1 g. 
Anti-nuclear antibody, Anti-ENA, ANCA, and cryoglobulins 
were negative, and C3 and C4 levels were normal. Hepatitis 
B surface antigen, anti-HBs, Anti-HAV , and Anti-HCV were 
also negative. His previous ultrasonography (USG) revealed 
bilaterally diminished kidney sizes (the right kidney measured 
90 × 40 mm, and the left kidney measured 85 × 45 mm). On 
a blood smear, atypical lymphocytes were seen, and bone 
marrow biopsy showed hypercellularity, with cells containing 
minimal cytoplasm and abnormal nuclear-cytoplasmic ratio. 
Flow cytometric studies of bone marrow tissues showed a 
population of T-cells that expressed CD2, CD3, CD4, CD5, 
CD7, and cytoplasmic CD3. These   findings were consis-
tent with precursor T-cell ALL. Despite the   combination 
of 5   different classes of antihypertensive therapy (ramipril 
10 mg/day,   losartan 100 mg/day,   amlodipin 10 mg/day, 
  doxazosin 4 mg/day, and intravenous nitroglycerin), and 
aquate hemodialysis, his blood pressure did not drop under 
180/110 mmHg. To establish the diagnosis, we performed 
abdominal computed tomography (CT), which showed 
  bilaterally enlarged kidneys (Figure 1). We consulted over the 
patient with a hematologist and initiated peripheral vascular 
disease (PVD) chemotherapy (  daunorubicine 45 mg/m2 per 
day for 7 days, vincristine 2 mg/m2 per day for 7 days, and 
prednisolone 64 mg/day for 28 days). To treat hyperuricemia, 
the patient was also given allopurinol and alkalized fluids, 
with ongoing hemodialysis. After the first cycle of PVD, his 
blood pressure dropped under 130/80 mmHg, and the renal 
USG revealed bilaterally atrophic kidneys. In this case, we 
hypothesized that ALL can bilaterally infiltrate the kidney in 
patients with ESRD. Kidney biopsy was considered before 
chemotherapy, but this procedure could not be performed 
because of uncontrolled hypertension and severe thrombo-
cytopenia. After the first chemotherapy, his neutrophil counts 
dropped under 500/mm 3, and febrile neutropenia developed. 
On the following days, despite the appropriate antibiotherapy, 
he had severe dyspnea and tachypnea. To establish the diag-
nosis, we performed thoracic CT.   Cavitary lesion   secondary 
to aspergillosis was diagnosed. We   initiated antifungal 
Table 1 Initial laboratory parameters of the patient
Parameter Value Normal range
White blood cell count (cells/mm3) 20,700 4,000–10,000
Neutrophils (cells/mm3) 6,400 2,500–7,500
Basophils (cells/mm3) 100 0–200
Lymphocytes (cells/mm3) 12,500 1,500–3,500
Monocytes (cells/mm3) 1,200 200–900
eosinophils (cells/mm3) 600 200–600
Hemoglobin (g/dL) 8.6 12–14
Mean corpuscular volume 89 80–96
Platelets (cells/mm3) 10,000 150,000–400,000
Urea (mg/dL) 90 17–43
Creatinine (mg/dL) 7.6 0.4–1.0
sodium (meq/L) 139 135–145
Potassium (meq/L) 4.3 3.5–5.5
Uric acid (mg/dL) 15.5 3.5–7.2
Lactate dehydrogenase (mg/dL) 990 98–192
Albumin (g/dL) 3.4 4.0–5.5
Iron (μg/dL) 117 50–170
TIBC (μg/dL) 108 255–450
Ferritine (ng/mL) 1,325 15–200
Abbreviation: TIBC, total iron binding capacity. Figure 1 Abdominal computed-tomography scan showing bilaterally enlarged kidneys.International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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therapy and the patient was entubated in an intensive care 
unit. Despite the intensive therapy, he died secondary to 
respiratory failure.
Discussion
ALL is a malignant disorder that orginates from a single 
B- or T-lymphocyte progenitor. The disease is most common 
in children but can occur at any age. ALL represents about 
12% of all leukemias diagnosed in United States, and 60% of 
all cases occur in patients younger than 20 years.2 Leukemic 
patients who are at a higher risk for extramedullary disease, 
including renal parencymal involvement, include those with 
T-cell ALL, as well as those with the M4 and M5 subtypes 
of acute myelogenous leukemia.1 Although ALL and its 
extramedullary infiltrations can frequently be seen in chil-
dren, these manifestations have also been reported in adults 
previously.3 The kidneys are the most frequent extramedullary 
site of leukemic infiltration, which was identified in 63% of 
autopsies performed on patients who had died with either 
lymphoid or myeloid leukemia.4 Kidney involvement of 
leukemic cells might be related to the embryological orgin 
of hematopoietic organ developments.5
We present a hemodialysis patient with new onset of uncon-
trolled hypertension, ESA-resistant anemia, thrombocytopenia, 
and Bell’s palsy, secondary to ALL. The case presented here 
is unusual because the patient did not have a previous history 
of ALL. Leukemic infiltration of the kidney is usually silent, 
and the hospital admission of patients with renal dysfunctions 
such as renal enlargement, hematuria, proteinuria, treatment-
resistant-hypertension, or acute kidney injury is uncommon. In 
a German multicenter trial of 938 adult patients with ALL, 10% 
of patients had organ infiltration, and only 0.4% had clinical 
evidence of renal involvement.6 Patients with enlarged kidneys 
may suffer abdominal fullness or pain. Physical examination 
reveals a palpable abdominal mass in 3%–5% of patients.7 
Multiple reports suggest that enlarged kidneys due to leukemic 
infiltration, detected by USG, CT, or excretory urography, is 
the most common imaging manifestation observed in renal 
involvement of ALL.1 Olgar et al showed that renal leukemic 
infiltration is a risk-factor for developing hypertension, and 
they also determined that hypertension might be a risk factor 
for renal parenchymal disease. In that study, hypertension was 
found in 21 out of 334 (6.3%) patients with ALL. Therefore, 
several factors affecting hypertension, such as age, elevated 
uric acid levels, blood transfusions, and treatment-induced 
encephalopathy should be considered.8 In the present case, 
he had well-controlled hypertension following treatment 
with an angiotensin-converting enzyme- (ACE) inhibitor and 
a calcium channel blocker (CCB). However, after the onset 
of ALL, the blood pressure of the patient did not drop under 
180/100 mmHg with 5 different groups of antihypertensive 
drugs, including ACE-inhibitor, angiotensin-receptor blocker, 
CCB, α-blocker, and intravenous nitroglycerin. We also 
hypothesized that the renin-angiotensin-aldosterone system 
may be responsible for his therapy-resistant hypertension, due 
to compression of tubules by leukemic cells. This hypothesis 
may clarify the treatment-resistant hypertension pathogenesis 
in the present case. Tumor lysis syndrome (TLS) is another 
important complication in ALL patients, especially those 
treated with chemotherapy. This syndrome may lead to both 
acute uric acid and phosphate nephropathy, which can also 
progress to acute renal failure. The patient presented had TLS, 
with increased uric acid and lactate dehyrogenase levels after 
chemotherapy that also contributed to resistant hypertension 
due to hyperuricemia.
Interestingly, the patient had Bell’s palsy before admission, 
which also supports leukemic cell infiltration. Prednisolone was 
given to treat the situation before admission, which could also 
have contributed to TLS and hypertension in this patient.
The patient presented here also had skin rashes, such as 
petechiae and dry purpura, when he was first admitted to 
our medical center. Since bleeding into the skin is one of the 
most common findings in thrombocytopenia, this part of the 
examination should be the most detailed. The differential diag-
noses of skin rashes in patients with thrombocytopenia vary 
according to concomitant symptoms and physical examination 
findings. Sites of bleeding should be noted, especially in the 
dependent parts of the body. These are normally the feet and 
ankles in ambulatory patients, but may be the presacral area 
in bedridden patients. Dry purpura is the term used when the 
only bleeding is in the skin. Wet purpura means that there 
is extensive mucous membrane bleeding. It is generally felt 
that the presence of wet purpura is the more serious, and is a 
prognostic sign for potentially life-threatening hemorrhage. 
Although rare, malignancy-associated vasculitis occurs more 
often with hematologic rather than solid malignancies. The 
classic presentation is that of a necrotizing leukocytoclastic 
vasculitis involving the skin, with palpable purpura, typically 
in dependent areas.9 It is hypothesized that tumor-related 
antigens, or cryoglobulins, form immune complexes, which 
are then deposited in the skin and result in a vasculitis. It may 
be especially common in acute myelomonocytic leukemia 
and precede the clinical onset of the leukemia. Systemic 
vasculitis in patients with lymphoproliferative disorders 
(lymphocytic lymphoma, Waldenstrom’s macroglobulinemia, 
or chronic lymphocytic leukemia) is most often caused by International Journal of Nephrology and Renovascular Disease
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  cryoglobulinemia.9   However, our patient did not have other 
clinical symptoms, such as fever, headache, arthralgia and 
myalgia, or laboratory findings of vasculitis, such as increased 
erythrocyte sedimentation rate, ANA, ANCA, cryoglobulins, 
or hepatitis B and C.
Conclusion
In conclusion, pathological findings such as uncontrolled 
hypertension, flank pain, skin rashes, and abnormal blood 
count could be a part of a systemic disease or malignany in 
patients with ESRD who are receiving renal replacement 
therapy. Although ALL and its extramedullary infiltrations can 
frequently be seen in children, these manifestations are also 
reported in adults. Leukemic cell infiltration of the kidneys 
can cause either renal failure, hypertension, or asymptomatic 
kidney enlargement. Treatments to be considered for hyperten-
sion associated with leukemic cell infiltration should include 
multiple drug combination, such as antihypertensive agents, 
chemotherapeutics, and antihyperuricemic agents. Despite the 
appropriate therapy, management of patients with ALL and 
ESRD is extremely difficult because of the complications with 
both the diseases and the medications.
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